Skip to main
NERV

Minerva Neurosciences (NERV) Stock Forecast & Price Target

Minerva Neurosciences (NERV) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Minerva Neurosciences is well-positioned to make a significant impact in the treatment of schizophrenia with its innovative drug candidate, roluperidone. The drug's strong efficacy and safety profile, along with its unique mechanism of action and potential for monotherapy use, make it a promising option for patients and investors alike. With a large market and ongoing clinical trials, the company has the potential for strong financial growth and success.

Bears say

Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on developing and commercializing proprietary product candidates for treating CNS diseases. Despite past trials demonstrating efficacy in schizophrenia patients with negative symptoms and mitigating potential adverse effects, their global Phase 3 trial did not meet statistical significance due to an elevated placebo effect, increasing risk and peak penetration potential. With the average age of onset of schizophrenia at ~26 years old and a large global market, Minerva has a significant opportunity for growth, but the company's current valuation is not justified.

Minerva Neurosciences (NERV) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Minerva Neurosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Minerva Neurosciences (NERV) Forecast

Analysts have given Minerva Neurosciences (NERV) a Buy based on their latest research and market trends.

According to 3 analysts, Minerva Neurosciences (NERV) has a Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Minerva Neurosciences (NERV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.